What We Do
We are a bioscience company dedicated to improving glycemic health and healthy aging. Our team, which includes high-experienced and cited scientists, is pioneering research and development of Glo1 inducer (GlucoRegulate) supplements which correct insulin resistance in overweight and obese subjects and improve regulation of glucose metabolism and insulin sensitivity which is associated with healthy aging. We are the innovators behind these optimized precision food supplements. We patented our flagship supplement trans-resveratrol and hesperetin combination (GlucoRegulate). This and related combinations are part of our patent portfolio.
Glocentrica Ltd is a company registered in the United Kingdom, based in Kenilworth, West Midlands.
Leadership
Professor Naila Rabbani, PhD
Paul J Thornalley, PhD
Executive Director
Professor Paul J Thornalley received his B.Sc. Chemistry from the University of Manchester, Manchester, U.K., in 1979 and D. Phil. Biochemistry in 1982 from University of Oxford, Oxford, U.K. He was Scientific Director, Diabetes Research Center, Qatar Biomedical Research Institute, Qatar, from 2018 – 2023 and Adjunct Professor, College of Health & Life Sciences, Hamad Bin Khalifa University (HBKU), Doha, Qatar, 2023 – 2025. He currently holds Executive Director/Director appointments in GloVitality Ltd (London, UK; Glovitality.com), Glocentrica Ltd (West Midlands, UK; Glocentrica.com) and iDiagnostix Ltd (West Midlands, UK; iDiagnostix.com).
He is a leading researcher and advocate in studies of the pathogenesis associated with hyperglycemia and also the reactive glucose-derived metabolite, methylglyoxal, and its metabolism by glyoxalase 1 (Glo1) of the glyoxalase system – in which he is considered founding investigator. He recently developed the “Hexokinase-linked glycolytic overload and unscheduled glycolysis” hypothesis of hyperglycemia-induced impaired incretin effect and pathogenesis in hepatic and peripheral insulin resistance, beta-cell glucotoxicity, type 2 diabetes and diabetic vascular complications.
In 1994, Thornalley led the first major clinical study showing exposure of patients with diabetes to profoundly increased levels of the reactive metabolite and glycating agent, methylglyoxal. In 2014, as Chief Investigating Office, he led the Healthy Aging Through Functional Food (HATFF or Hats-off) clinical trial of optimized Glo1 inducer food supplement, trans-resveratrol and hesperetin, finding that Glo1 inducer corrected insulin resistance in overweight and obese subjects.
In the past decade, he has led investigations into how increased methylglyoxal and other metabolic dysfunction drives development of glycemic disease – insulin resistance, pancreatic beta-cell failure, and the development of type 2 diabetes and related vascular complications. From this emerged the “Hexokinase-linked glycolytic overload and unscheduled glycolysis” hypothesis of glycemic disease, identification of increased methylglyoxal as major activator of the unfolded protein response, GlucoRegulate may provide adjunct/standalone therapy when coming off treatment with GLP-1 and GLP-1/GIP agonist and GlucoRegulate may provide treatment for early-stage MASLD.
Naila Rabbani, PhD
Director
Professor Naila Rabbani received her B. Sc. Biological & Medicinal Chemistry in 1998 and PhD Biochemistry in 2002 from University of Essex, Colchester, U.K. She was Adjunct Professor of Basic Medical Sciences, College of Medicine, Qatar, 2020 – 2023. She currently holds Executive Director/Director appointments in GloVitality Ltd (London, UK; Glovitality.com), Glocentrica Ltd (West Midlands, UK; Glocentrica.com) and iDiagnostix Ltd (West Midlands, UK; iDiagnostix.com). She is a biomedical research scientist with over 25 years’ experience in clinical translational research. She is a leading international expert in protein glycation research in which she developed the AGEomics technology and pioneered the application of artificial intelligence (AI) machine learning for the development of diagnostic algorithms with protein glycation biomarkers as features.
In 2014, Rabbani, then faculty member at Warwick Medical School, led protein glycation analysis in the Healthy Aging Through Functional Food clinical trial of glyoxalase 1 (Glo1) inducer, trans-resveratrol and hesperetin, finding that Glo1 inducer decreased protein glycation by methylglyoxal and metabolism-linked low-grade inflammation, and corrected insulin resistance in overweight and obese subjects.
In the past decade, Professor Rabbani has made multiple seminal contributions to the causes and consequences of increased methylglyoxal concentration, dicarbonyl stress, and related protein glycation – including its origin in insulin resistance, beta-cell glucotoxicity and diabetes, consequences for increased metabolic stress and inflammation through activation of the unfolded protein response, and methylglyoxal protein glycation adducts as diagnostic indicators of glycemic disease. Her latest research has shown plasma protein glycation and oxidation markers provide features in a diagnostic screening test for autism and methylglyoxal glycation adducts correlate positively with the severity of autism – opening a new approach to a blood test for screening for autism and blood test for assessment of autism severity.
Achievements of Directors
Over 40 years of pioneering experience and expertise in dysfunction glucose metabolism in insulin resistance, obesity, diabetes, related vascular complications of diabetes, other disease and disorders and aging
Founding research and development of physiological formation, metabolism and function of reactive metabolite methylglyoxal
Over 40 years of Award-Winning Excellence in Academic Research
Glocentrica Ltd created as a spinout company in 2019
Our sister company, Glovitality (UK) Ltd, incorporated in 2024, markets Glo1 inducer supplement, GlucoRegulate, under license from Glocentrica Ltd.
Our Directors are highly accomplished scientists:
Professor Paul J Thornalley has published 334 Peer-Reviewed Publications, including 10+ Clinical Studies and 4 Industry Awards. Google scholar
Professor Rabbani has published 163 Peer-Reviewed Publications, including 10+ Clinical Studies and 4 Industry Awards. Google Scholar